Hepatitis C virus (HCV) is estimated to infect around 170 million people worldwide; although it is curable, underdiagnosis means that as few as one in 100 sufferers is receiving the appropriate treatment. Hepatitis B infects around 2 billion people – one in three people worldwide. Of these, many will develop chronic liver disease, resulting in an estimated 1 million deaths a year worldwide from cirrhosis and liver cancer. There are new treatments for Hepatitis B and C. It is important to make an early diagnosis, as this correlates with a better prognosis. There is a specialised team of consultants who manage particularly complex cases, such as those with resistance to previous antiviral treatment and patients with multiviral co-infection. We have a dedicated laboratory on site to process samples for viral drug resistance – an essential component of care.
We can use a transjuglar liver biopsy which is less painful for patients, enables better samples to be taken and involves a much shorter hospital stay. Where a liver biopsy is inappropriate, transient elastography (Fibroscan) can be performed. Our specialist nurses act as a link between the consultants and patients and are able to follow patients very closely day to day if necessary whilst they have therapy and in order to give support and advice.
To book an appointment with one of our consultants, please contact our enquiries team on:
Tel: 020 7317 7751